๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Bcl-6, a Prognostic Biomarker in Diffuse Large B-Cell Lymphoma

โœ Scribed by Shivakumar, Latha; Jain, Vinay K.

Book ID
118629188
Publisher
CIG Media Group, LP.
Year
2006
Tongue
English
Weight
120 KB
Volume
7
Category
Article
ISSN
1557-9190

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Biomarkers of potential prognostic signi
Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma
โœ Grace Wu; Armand Keating ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 116 KB

## Abstract Diffuse large Bโ€cell lymphoma (DLBCL) is a biologically heterogeneous disease for which the current approach to treatment is only successful for 50% of patients. The prognostic value of various clinical and biological factors in predicting treatment outcome is discussed in this paper. A

BCL2 mutations in diffuse large B-cell l
BCL2 mutations in diffuse large B-cell lymphoma
โœ Schuetz, J M; Johnson, N A; Morin, R D; Scott, D W; Tan, K; Ben-Nierah, S; Boyle ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› Nature Publishing Group ๐ŸŒ English โš– 400 KB

BCL2 is deregulated in diffuse large B-cell lymphoma (DLBCL) by the t(14;18) translocation, gene amplification and/or nuclear factor-kB signaling. RNA-seq data have recently shown that BCL2 is the most highly mutated gene in germinal center B-cell (GCB) DLBCL. We have sequenced BCL2 in 298 primary D

Prognostic models for diffuse large b-ce
Prognostic models for diffuse large b-cell lymphoma
โœ Annarita Conconi; Emanuele Zucca; Enrico Roggero; Francesco Bertoni; Augusto Ber ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 106 KB ๐Ÿ‘ 2 views

Prognosis of DLCL patients is variable and associated with well-deยฎned risk factors. In the past decade several pretreatment variables have been incorporated into prognostic models to predict the death risk of individual patients. The International Prognostic Index (IPI), developed in an internation